Skip to main content
. Author manuscript; available in PMC: 2021 May 13.
Published in final edited form as: Amyotroph Lateral Scler Frontotemporal Degener. 2020 Sep 24;22(3-4):287–299. doi: 10.1080/21678421.2020.1822410

Figure 2.

Figure 2.

LS mean change from baseline for each group from a mixed model analysis of (A) percent predicted SVC (primary endpoint), (C) ALSFRS-R total score, and (E) muscle strength mega-score. Post hoc analysis of LS mean change from baseline from a mixed model analysis for all reldesemtiv-treated patients versus placebo for (B) percent predicted SVC, (D) ALSFRS-R Total Score, and (F) muscle strength mega-score. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; bid, twice daily; BL: baseline; LS: least squares; SE: standard error; SVC: slow vital capacity; wk: week.